BLA 761485 · Denali Therapeutics Inc.
Avlayah
Tividenofusp Alfa-Eknm · Powder,For Solution · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Mar 24, 2026: To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Mar 24, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
2 Phase 3, 0 recruiting
FAERS reports
8
7 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies, including AVLAYAH, have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate AVLAYAH in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue AVLAYAH and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS...
What it is approved for
From the label in effect Mar 20, 2026.
AVLAYAH is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. This indication is approved under accelerated approval based on the reduction of cerebrospinal fluid heparan sulfate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Limitations of Use AVLAYAH is not recommended for use in combination with other enzyme replacement therapies for the treatment of Hunter syndrome. AVLAYAH is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. ( 1 ) This indication is approved under accelerated approval based on reduction of cerebrospinal fluid heparan sulfate observed in patients treated with AVLAYAH. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) Limitations of Use AVLAYAH is not recommended for use in combination with other enzyme replacement therapies. ( 1 )
Mechanism: Hunter syndrome is an inherited X-linked recessive lysosomal storage disease caused by a deficiency of iduronate-2-sulfatase (IDS), a lysosomal enzyme, that degrades heparan sulfate (HS) and dermatan sulfate (DS), the two primary glycosominoglycans (GAGs) in the lysosome. Insufficiency or absence of IDS leads to accumulation of GAGs, including HS and DS, and subsequent lysosome dysfunction in multiple organs and tissues, including the central nervous system (CNS). Tividenofusp alfa-eknm provides an exogenous source of IDS. The fragment, crystallizable (Fc) component of tividenofusp alfa-eknm...
Therapeutic areas: Neurology · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 24, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- AVLAYAH · TIVIDENOFUSP ALFA-EKNM 150MG/VIAL · INJECTION, POWDER,FOR SOLUTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tividenofusp Alfa" as an intervention, any sponsor and status, largest first.
- An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007Pivotal-lookingEnrolling by invitation
Denali Therapeutics Inc.Industry
NCT06075537 · 99 participants (planned) · Start Sep 20, 2023 · Primary completion Jun 2027
Drug: tividenofusp alfa · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Hackensack, New Jersey · 32 sites in all
- A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)Pivotal-lookingActive, not recruiting
Denali Therapeutics Inc.Industry
NCT05371613 · 65 participants · Start Jul 21, 2022 · Primary completion Dec 2027
Drug: tividenofusp alfa; idursulfase · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Hackensack, New Jersey · 30 sites in all
- A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter SyndromeActive, not recruiting
Denali Therapeutics Inc.Industry
NCT04251026 · 47 participants · Start Jul 16, 2020 · Primary completion Feb 2031
Drug: tividenofusp alfa · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Chapel Hill, North Carolina · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infusion related reaction5
- cough3
- oxygen saturation decreased3
- urticaria3
- dyspnoea2
- chills1
- discomfort1
- erythema1
- eye swelling1
- flushing1
- hypopnoea1
- hypoxia1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II.
Muenzer J, Burton BK, Harmatz P, et al. · N Engl J Med 2026 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: Denali Therapeutics Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.